Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
VELETRI Market Size Outlook: How Fast Will Revenue Grow Through 2030?
A notable expansion has characterized the veletri market in recent times. Projections indicate an increase from $1.45 billion in 2025 to $1.56 billion in 2026, representing a compound annual growth rate of 7.7%. The growth witnessed historically can be linked to the clinical efficacy of epoprostenol, a higher incidence of PAH diagnosis, the reliance of hospitals on IV prostacyclins, the limited array of oral medications, and improved survival prospects for individuals with PAH.
The veletri market is projected to experience robust growth over the coming years, reaching a valuation of $2.07 billion by 2030 with a compound annual growth rate (CAGR) of 7.4%. This anticipated expansion is driven by several factors during the forecast period, including the rising incidence of pulmonary arterial hypertension (PAH), the emergence of specialized PAH treatment centers, a growing need for stable drug formulations, broader adoption of infusion therapies, and enhanced public awareness about PAH. Key developments shaping the market include an increasing preference for prostacyclin therapies that do not require refrigeration, a higher uptake of continuous infusion PAH treatments, a growing demand for advanced vasodilators tailored to PAH, the expansion of hospital-based programs for PAH management, and a stronger emphasis on improving mobility and quality of life for PAH patients.
Download A Free Sample Report For Comprehensive Market Insights:
VELETRI Market Opportunity Drivers: What Is Creating New Revenue Potential?
The anticipated growth of the VELETRI market is being driven by the rising occurrence of venous conditions. These disorders involve impaired blood flow within the veins, leading to symptoms such as swelling, pain, and potential complications like varicose veins and deep vein thrombosis. Several factors contribute to this upward trend, including an aging demographic, sedentary habits, increasing obesity rates, and enhanced diagnostic techniques. Veletri is prescribed to boost exercise tolerance and alleviate symptoms for patients suffering from venous diseases affecting the pulmonary vessels. For example, data from the Centers for Disease Control and Prevention, a US government entity, revealed in January 2025 that venous thromboembolism (VTE) impacts as many as 900,000 people annually in the United States, with an estimated 60,000 to 100,000 deaths occurring each year due to this clotting disorder. Consequently, the growing prevalence of venous diseases is fueling the expansion of the VELETRI market.
The VELETRI market is poised for expansion due to increasing healthcare spending. This expenditure encompasses all financial resources dedicated to medical goods and services aimed at maintaining and enhancing public health. The rise in healthcare spending is largely because an older population requires more frequent medical attention and long-term care services. Greater financial investment in healthcare facilitates broader utilization of VELETRI by enhancing access to specialized pulmonary arterial hypertension (PAH) care, expanding coverage for expensive treatments, and strengthening the clinical framework necessary for continuous intravenous therapy. As an illustration, the Office for National Statistics, a UK-based governmental body, reported in April 2025 that total healthcare spending grew by 6.5% in nominal terms and by 2.4% in real terms, after adjusting for inflation, between 2023 and 2024. Hence, the rise in healthcare expenditure is propelling the VELETRI market forward.
VELETRI Market Segment Analysis Highlighting Growth Areas
The veletri market covered in this report is segmented –
1) By Formulation Stability Type: Room-Temperature Stable Formulation, Refrigeration-Required Formulation
2) By Treatment Setting: Hospitals, Specialized Pulmonary Hypertension Centers
3) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies
Subsegments:
1) By Room-Temperature Stable Formulation: Ready-to-Use Formulation, Extended Stability Infusion Solution
2) By Refrigeration-Required Formulation: Reconstituted Cold-Chain Formulation, Limited-Stability Infusion Solution
VELETRI Market Innovation Trends Driving Future Development
Leading players in the Veletri market are prioritizing greater accessibility through the introduction of generic alternatives, like the FDA-cleared epoprostenol sodium injection, aimed at offering more affordable treatment solutions for individuals with pulmonary arterial hypertension. Generic Veletri consists of bioequivalent versions of the original epoprostenol product, conforming to FDA requirements for quality, safety, and effectiveness, thus delivering identical clinical advantages at a reduced cost. A case in point is Mylan Pharmaceuticals, a U.S.-based drug manufacturer, which obtained FDA authorization in October 2025 for its generic Veletri (epoprostenol sodium) injection. This product is available in various vial sizes, such as 20 mg/20 mL, 50 mg/20 mL, 100 mg/20 mL, and 200 mg/20 mL, and offers the same prostacyclin mimetic effect as the brand-name drug, aiding in enhanced exercise capacity and symptom control for PAH patients.
VELETRI Market Leading Companies: Who Holds Significant Market Presence?
Major companies operating in the veletri market are Johnson & Johnson, Bayer Pharma AG, Novartis AG, GlaxoSmithKline plc, Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Sandoz International GmbH, Sun United Therapeutics Corporation, Actelion Pharmaceuticals Ltd., Bayer Pharma AG, GlaxoSmithKline plc, Novartis AG, Pfizer Inc., Johnson & Johnson, Sandoz International GmbH, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Euroapi S.A., Pfizer CentreOne, Sai Life Sciences Limited, Zhejiang Ausun Pharmaceutical Co. Ltd., Yonsung Fine Chemicals Co. Ltd., Cayman Pharma S.r.o., Nichi-Iko Pharmaceutical Co. Ltd., Dr. Reddy’s Laboratories Ltd., Aurobindo Pharma Ltd., Hikma Pharmaceuticals plc
Access The Complete VELETRI Market Report:
VELETRI Market Regional Analysis And Leading Geography
North America was the largest region in the VELETRI market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the veletri market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model